MetaVia Inc. (MTVA)
Nasdaq: MTVA · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2015
Filings
441 filings since 2017 beside 119 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 44 days after the quarter ended. The proxy statement was last filed Apr 27, 2026.
Filings a yearinsider forms included
6344654855655959
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Jun 8, 2026.Listing warning from its exchange (8-K item 3.01): 2 times in the last 36 months, the newest Nov 26, 2025.SEC letters: 15 in the last 36 months, the newest Jan 14, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 13, 2026
10-Q
Quarterly reportThe SI's read MetaVia, a clinical stage drug developer with no revenue, reported a net loss of $13.8 million for the nine months ended September 30, 2026 and held $8.8 million in cash and cash equivalents. The company states substantial doubt about its ability to continue as a going concern, meaning it may not be able to pay its bills for the next year without new funding. The tag is concerning because of that going concern warning and the thin cash balance.
Sep 30, 2026
Nov 13, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current reportThe SI's read MetaVia reported a third quarter 2026 net loss of $4.6 million, against $3.4 million a year earlier, as research spending on its drug candidate DA-1726 rose, and cash fell to $8.8 million from $10.3 million at December 31, 2025. The company reported interim trial data showing a 68.1% placebo-adjusted reduction in liver fat and said it plans a 48-week Phase 2 study targeted for the second half of 2027. The tag is neutral because encouraging early data sits beside a wider loss and a small cash balance.
Nov 5, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Oct 13, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Sep 9, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Aug 6, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Jul 9, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Jun 8, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Jun 8, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
May 14, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Mar 18, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Jan 16, 2026
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Jan 15, 2026
40 of 441 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.